肺动脉高压药物治疗现状和发展趋势

肺动脉高压(PH)是一种以肺小动脉痉挛、内膜增生与重构为主要特征,最终导致肺循环阻力进行性增加右心功能衰竭、功能严重受损甚至死亡的疾病。它具有药物治疗效果和预后差的特点。近年来,PH在单一药物治疗上虽取得了一定疗效,但单一药物治疗在临床上有较大的局限性。联合药物治疗则可以发挥药物间的协同效应,降低单个药物的不良反应。

The Current Situation and Development Trend in Drug Treatment of Pulmonary Hypertension

Pulmonary hypertension(PH)is primarily characterized by vascular spasm,proliferation and remodeling in small pulmonary arteries,which eventually leads to right heart failure,severe functional limitations,and ultimately death.It has the characteristics of poor drug therapeutic effects and poor prognosis.In recent years,some developments in the pharmacological management of monotherapy for PH has been made,however,monotherapy in clinical has certain limitations.Combination therapy has enhanced the efficacy,and decreased the adverse effects of monotherapy.